Merck & Co. Inc. (MRK)
-NYSE | Prev Close: | 47.75 |
|---|
| Open: | N/A |
|---|
| Bid: | 47.22 x 200 |
|---|
| Ask: | 48.24 x 200 |
|---|
| 1y Target Est: | 52.33 |
|---|
| Beta: | 0.37 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 39.00 - 50.16 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 18,503,000 |
|---|
| Market Cap: | 144.19B |
|---|
| P/E (ttm): | 24.36 |
|---|
| EPS (ttm): | 1.96 |
|---|
| Div & Yield: | 1.72 (3.60%) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Featured on Yahoo! Finance
Headlines
- AstraZeneca, Bristol diabetes drug disappoints in key testat Reuters(Wed 2:55AM EDT)
- The Dow's Triple-Digit Gains Left These Stocks Behindat Motley Fool(Tue, Jun 18)
- GE Stock Leads Dow’s 138-Point Surgeat Motley Fool(Tue, Jun 18)
- Merck Stock Lags Solid Gains on Wall Streetat Motley Fool(Tue, Jun 18)
- Top Treatments for High Cholesterolat Motley Fool(Tue, Jun 18)
- Largest option buying in equities so faroptionMONSTER(Tue, Jun 18)
- Supreme Court Permits Antitrust Scrutiny Of Pharma Settlementsat Forbes(Tue, Jun 18)
- Where Is Biotechnology's Next 'Anti-PD-1'?at Seeking Alpha(Tue, Jun 18)
- Drugmakers Opened to ‘Pay for Delay’ Suits by High Courtat Bloomberg(Mon, Jun 17)
- R&D Spending Holds Potential As A Game-Changer For StocksInvestor's Business Daily(Mon, Jun 17)
- Blood tests could detect sexually-transmitted oral cancersat Reuters(Mon, Jun 17)
- The Top Ten Stocks for June 17at Bloomberg(Mon, Jun 17)
- Abbott Loves Abbott Laboratories Stockat Motley Fool(Mon, Jun 17)
- Pfizer Sues to Block Generic AzaSite Sales and 2 More Heavily Traded Stocks to Followat Wall St. Cheat Sheet(Mon, Jun 17)
- Markets Rally on Hope of Continued Fed Stimulusat Motley Fool(Mon, Jun 17)
Press Releases
- Litigation Settlements, Data Compliance Reviews, and Clinical Trials Pave Way for Solid Footing in Healthcare - Research Report on Pfizer, Merck, Bristol-Myers Squibb, Keryx and Pacira PharmaceuticalsPR Newswire(Mon, Jun 17)
- Merck Welcomes Independent Review of the Safety Profile of JANUVIA® (sitagliptin) and Other Diabetes MedicinesBusiness Wire(Wed, Jun 12)
- Merck Announces Presentation of Interim Data from Study Evaluating Lambrolizumab, an Investigational Anti-PD-1 Antibody, in Patients with Advanced Melanoma at ASCO 2013Business Wire(Sun, Jun 2)
Key Statistics
| Forward P/E (1 yr): | 12.77 |
|---|
| P/S (ttm): | 3.12 |
|---|
| Ex-Dividend Date: | 13-Jun-13 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 3.50 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.84 |
|---|
| Mean Recommendation*: | 2.2 |
|---|
| PEG Ratio (5 yr expected): | 4.49 |
|---|
Business Summary
Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide.
View More 
0.91%